Advertisement

Mammakarzinom pp 109-118 | Cite as

Endokrine Therapie des Mammakarzinoms

  • G. Reiner
Part of the Angewandte Onkologie book series (AONKOLOGIE)

Zusammenfassung

Das normale Brustdrüsengewebe unterliegt einer Reihe von hormonellen Einflüssen. Die Beeinflußbarkeit kann auch nach maligner Transformation von Brustdrüsenzellen erhalten bleiben und macht somit endokrine Therapieformen beim Mammakarzinom möglich. Seit den ersten Beobachtungen von Beatson [1] und Schinzinger [2] vor fast 100 Jahren, daß die Ovarektomie eine Remission eines fortgeschrittenen Mammakarzinoms induzieren konnte, wurde eine Vielzahl von ablativen und additiven endokrinen Therapieformen versucht. Die Bedeutung dieser Therapieform muß immer wieder betont werden, da nicht nur Symptome gemildert werden, sondern auch zumindest bei postmenopausalen Patientinnen statistisch gesichert ist, daß das rezidivfreie und auch das Gesamt-Überleben verbessert werden können [3]. Außerdem sind endokrine Therapieformen nebenwirkungsarm und weniger toxisch als eine zytotoxische Chemotherapie. Die Entdeckung der Steroidhormonrezeptoren in den sechziger Jahren [4] und 1967 jener in Mammakarzinomzellen [5] haben wesentlich zum Verständnis der hormonellen Beeinflußbarkeit des Mammakarzinoms beigetragen, und der Steroidhormonrezeptormechanismus stellt den entscheidenden Ansatzpunkt der heutigen endokrinen Therapiemodalitäten dar.

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

Literatur

  1. 1.
    Beatson GT (1896) On the treatment of inoperable cases of carcinoma of the mamma: suggestions for a new method of treatment with illustrative cases. Lancet ii: 162CrossRefGoogle Scholar
  2. 2.
    Schinzinger K (1905) Das Karzinom der Mamma. Münch Med Wochenschr 2: 1724Google Scholar
  3. 3.
    Peto R (1988) Effects of adjuvant tamoxifen and of cytotoxic therapy on mortality in early breast cancer. An overview of 61 randomized trials among 28.896 women. N Engl J Med 319: 1681Google Scholar
  4. 4.
    Toft D, Gorski J (1966) A receptor molecule for estrogens: isolation from the rat utery and preliminary characterization. Proc Natl Acad Sci USA 55: 1574PubMedCrossRefGoogle Scholar
  5. 5.
    Jensen EV, De Sombre ER, Jungblut PW (1967) Estrogen receptors in hormone-responsive tissues and tumors. In: Wissler RW (ed) Endogenous factors influencing host tumor balance. University of Chicago Press, Chicago, p 68Google Scholar
  6. 6.
    Molteni A, Bahu RM, Batifora HA, et al (1979) Estradiol receptor assays in normal and neoplastic tissues. A possible diagnostic aid for tumor differentiation. Ann Clin Lab Sci 9: 103PubMedGoogle Scholar
  7. 7.
    Katzenellenbogen BS (1980) Dynamics of steroid hormone receptor action. Ann Rev Physiol 42: 17CrossRefGoogle Scholar
  8. 8.
    Butler WB, Kirkland WL, Gargola TL, et al (1983) Steroid stimulation of plasminogen activator production in a human breast cancer cell line (MCF-7). Cancer Res 43: 1637PubMedGoogle Scholar
  9. 9.
    Eckert RL, Katzenellenbogen BS (1982) Effects of estrogens and antiestrogens on estrogen receptor dynamics and the induction of progesterone receptor in MCF-7 human breast cancer cells. Cancer Res 42: 139PubMedGoogle Scholar
  10. 10.
    Lippman M, Bolan G, Huff K (1976) The effects of estrogens and antiestrogens on hormone-responsive human breast cancer in long-term tissue culture. Cancer Res 36: 4595PubMedGoogle Scholar
  11. 11.
    Mange! WF, Toledo DL, Nardulli AM, et al (1988) Plasminogen activators in human breast cancer cell lines: hormonal regulation and properties. J Steroid Biochem 30: 79CrossRefGoogle Scholar
  12. 12.
    Sporn MB, Todaro G) (1980) Autocrine secretion and malignant transformation of cells. N Engl J Med 303: 878PubMedCrossRefGoogle Scholar
  13. 13.
    Jakesz R, Smith CA, Aitken S, et al (1984) Influence of cell proliferation and cell cycle phase on expression of estrogen receptor in MCF-7 breast cancer cells. Cancer Res 44: 619PubMedGoogle Scholar
  14. 14.
    Lippman ME (1988) Steroid hormone receptors and mechanisms of growth regulation of human breast cancer. In: Lippman ME, Lichter AS, Danforth DN (eds) Diagnosis and management of breast cancer. Saunders, Philadelphia, p 326Google Scholar
  15. 15.
    Jakesz R, Kees A, Kolb R, et al (1982) Östrogen-and Progesteronrezeptoren beim primären Mammakarzinom. In: Jonat W, Maas H (Hrsg) Steroidhormonrezeptoren im Karzinomgewebe. Enke, Stuttgart, S 31Google Scholar
  16. 16.
    Reiner G, Jakesz R, Kolb R, et al (1988) Androgenrezeptoren beim primären Mammakarzinom: Beziehungen zu Prognosefaktoren im Vergleich mit Östrogen-and Progesteronrezeptoren. Dtsch Med Wochenschr 113: 892PubMedCrossRefGoogle Scholar
  17. 17.
    Reiner A, Reiner G, Spona J, et al (1988) Histopathologic characterization of human breast cancer in correlation with estrogen receptor status. A comparison of immunocytochemical and biochemical analysis. Cancer 61: 1149PubMedCrossRefGoogle Scholar
  18. 18.
    Reiner A, Kolb R, Reiner G, et al (1987) Prognostic significance of steroid hormone receptors and histopathological characterization of human breast cancer. J Cancer Res Clin Oncol 113: 285PubMedCrossRefGoogle Scholar
  19. 19.
    Kolb R, Reiner G, Jakesz R, et al (1979) Topische Unterschiede im Östrogenrezeptorgehalt primärer Mammakarzinome. In: Junghanns H (Hrsg) Chirurgisches Forum 1979 für experimentelle and klinische Forschung. Springer, Berlin Heidelberg New York, S 179Google Scholar
  20. 20.
    Jakesz R, Dittrich Ch, Hanusch J, et al (1985) Simultaneous and sequential determinations of steroid hormone receptors in human breast cancer. Influence of intervening therapy. Ann Surg 201: 305PubMedCrossRefGoogle Scholar
  21. 21.
    Allegra JC, Barlock A, Huff KK, et al (1980) Changes in multiple or sequential estrogen receptor determinations in breast cancer. Cancer 45: 792PubMedCrossRefGoogle Scholar
  22. 22.
    Mc Guire WL, Vollmer EP, Carbone PP (1975) Estrogen receptors in human breast cancer. Raven Press, New YorkGoogle Scholar
  23. 23.
    Reiner A, Neumeister B, Spona J, et al (1990) Immunocytochemical localization of estrogen and progesterone receptor and prognosis in human primary breast cancer. Cancer Res 50: 7057PubMedGoogle Scholar
  24. 24.
    Bryant AJS, Weir JA (1981) Prophylactic oophorectomy in operable instances of carcinoma of the breast. Surg Gynecol Obstet 153: 660PubMedGoogle Scholar
  25. 25.
    Nissen-Meyer R (1967) The role of prophylactic castration in the therapy of human mammary cancer. Eur J Cancer 3: 395PubMedGoogle Scholar
  26. 26.
    Cole MP (1968) Suppression of ovarian function in primary breast cancer. In: Forrest APM, Kunkler PB (eds) Prognostic factors in breast cancer. Livingston, Edinburgh, p 146Google Scholar
  27. 27.
    Meakin JW (1986) Review of Canadian trials of adjuvant endocrine therapy of breast cancer. NCI Monographs 1: 111PubMedGoogle Scholar
  28. 28.
    Kaufmann M (persönliche Mitteilung)Google Scholar
  29. 29.
    Nolvadex Adjuvant Trial Organization (1985) Controlled trial of tamoxifen as single adjuvant agent in management of early breast cancer. Lancet i: 836Google Scholar
  30. 30.
    Goldhirsch A, Gelber R (1986) Adjuvant treatment for early breast cancer. The Ludwig Breast Cancer Studies. NCI Monographs 1: 55PubMedGoogle Scholar
  31. 31.
    Mouridson HT, Andersen AP, Brinker H, et al (1986) Adjuvant tamoxifen in postmenopausal high-risk breast cancer patients. Present status of the Danish breast cancer cooperative group trials. NCI Monographs 1: 115Google Scholar
  32. 32.
    Cummings FJ, Gray R, Davis TE, et al (1986) Tamoxifen vs placebo: double blind adjuvant trial in elderly women with stage II breast cancer. NCI Monographs 1: 119PubMedGoogle Scholar
  33. 33.
    Tormey DC, Gray R, Taylor SG, et al (1986) Postoperative chemotherapy and chemohormonal therapy in women with nodal positive breast cancer. NCI Monographs 1: 75PubMedGoogle Scholar
  34. 34.
    Kaufmann M, Maass H, Kubli F, et al (1984) Risk adapted adjuvant chemohormone therapy in operable nodal positive breast cancer. In: Jones SE, Salmon SE (eds) Adjuvant therapy of cancer IV. Grune Stratton, Orlando, p 369Google Scholar
  35. 35.
    Pannuti F, Martoni A, Di Marco AR, et al (1979) Prospective randomized clinical trial of two different high dosages of medroxy-progesterone acetate ( MAP) in the treatment of metastatic breast cancer. Eur J Cancer 15: 593PubMedGoogle Scholar
  36. 36.
    McIntosh IH, Thynne GS (1977) Tumor stimulation by antiestrogens. Br J Surg 64: 900PubMedCrossRefGoogle Scholar
  37. 37.
    Jordan VC (1984) Bischemical pharmacology of antiestrogen action. Pharmacol Rev 36: 245PubMedGoogle Scholar
  38. 38.
    Furr BJA, Jordan VC (1984) The pharmacology and clinical uses of tamoxifen. Pharmacol Ther 25: 127PubMedCrossRefGoogle Scholar
  39. 39.
    Patterson JS, Battersby LA, Edwards DG (1982) Review of the clinical pharmacology and international experience with tamoxifen in advanced breast cancer. Rev Endocr Rel Cancer [Suppl 9]: 563Google Scholar
  40. 40.
    Pritchard KI, Thomson DB, Myers RE, et al (1980) Tamoxifen therapy in premenopausal patients with metastatic breast cancer. Cancer Treat Rep 64: 787PubMedGoogle Scholar
  41. 41.
    Santen RS, Lipton A, Kendall J (1974) Successful medical adrenalectomy with aminoglutethimide. Role of altered drug metabolism. JAMA 230: 1661PubMedCrossRefGoogle Scholar
  42. 42.
    Santen RJ, Worgul TJ, Samojlik E, et al (1981) Randomized trial comparing surgical adrenalectomy with aminoglutethimide plus hydrocortisone in women with advanced breast cancer. N Engl J Med 305: 545PubMedCrossRefGoogle Scholar
  43. 43.
    Coombes RC, Goss P, Dowsett M, et al (1984) 4-Hydroxyandrostendione in treatment of postmenopausal patients with advanced breast cancer. Lancet i:1237Google Scholar
  44. 44.
    Kaufmann M, Jonat W, Kleeberg V, et al (1989) Goserelin, a depot gonadotropinereleasing hormone agonist in the treatment of premenopausal patients with metastatic breast cancer. J CI in Oncol 7: 1113Google Scholar

Copyright information

© Springer-Verlag/Wien 1992

Authors and Affiliations

  • G. Reiner

There are no affiliations available

Personalised recommendations